ABBV-3373-A NOVEL IMMUNOLOGY ANTIBODY DRUG CONJUGATE: RESULTS FROM A FIRST-IN-HUMAN SINGLE ASCENDING DOSE STUDY IN HEALTHY SUBJECTS TO SUPPORT DOSE SELECTION FOR THE PROOF-OF-CONCEPT STUDY IN RHEUMATOID ARTHRITIS PATIENTS.

被引：0
|
作者：
D'Cunha, R. [1 ]
Kupper, H. [2 ]
Arikan, D. [1 ]
Zhao, W. [1 ]
Ruzek, M. [3 ]
Kang, B. [3 ]
Doelger, E. [2 ]
Carter, D. [1 ]
Pang, Y. [1 ]
机构：
[1] AbbVie, N Chicago, IL 60064 USA
[2] AbbVie Deutschland, Ludwigshafen, Germany
[3] AbbVie Biores Ctr, Worcester, MA USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2021年 / 109卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PIV-058
引用
收藏
页码：S78 / S79
页数：2
相关论文
共 25 条
  • [1] A first-in-human study of the novel immunology antibody-drug conjugate, ABBV-3373, in healthy participants
    D'Cunha, Ronilda
    Kupper, Hartmut
    Arikan, Dilek
    Zhao, Weihan
    Carter, David
    Blaes, Jonas
    Ruzek, Melanie
    Pang, Yinuo
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2024, 90 (01) : 189 - 199
  • [2] Dose escalation results from a first-in-human study of ABBV-400, a novel c-Met-targeting antibody-drug conjugate, in advanced solid tumors
    Sharma, Manish
    Kuboki, Yasutoshi
    Camidge, D. Ross
    Perets, Ruth
    Sommerhalder, David
    Yamamoto, Noboru
    Bar, Jair
    Parikh, Apurvasena
    Li, Rui
    Thiele, Gladys Morrison
    Aristide, Martha Raluca Neagu
    Freise, Kevin Jay
    Powderly, John D.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [3] EFFICACY AND SAFETY OF ABBV-3373, A NOVEL ANTI-TNF GLUCOCORTICOID RECEPTOR MODULATOR ANTIBODY DRUG CONJUGATE, IN PATIENTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS DESPITE METHOTREXATE THERAPY: A PHASE 2A PROOF OF CONCEPT STUDY
    Buttgereit, F.
    Aelion, J.
    Rojkovich, B.
    Zubrzycka-Sienkiewicz, A.
    Radstake, T.
    Chen, S.
    Arikan, D.
    Kupper, H.
    Amital, H.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 64 - 64
  • [4] A Bispecific Agonistic Antibody to FGF-R1/KlothoB Improves the Cardiometabolic Profile in Otherwise Healthy Obese Subjects: Preliminary Results from the First-in-Human Single Ascending Dose Study
    Arora, Puneet S.
    Wong, Chin
    Baruch, Amos
    Chinn, Leslie
    Vaze, Anjali
    Lewin-Koh, Nicholas
    Morrow, Linda
    Chen, Shan
    Boismenu, Richard
    DIABETES, 2017, 66 : A290 - A290
  • [5] A first-in-human, phase 1, dose-escalation study of ABBV-176, an antibody-drug conjugate targeting the prolactin receptor, in patients with advanced solid tumors
    Charlotte Lemech
    Natasha Woodward
    Nancy Chan
    Joanne Mortimer
    Louie Naumovski
    Silpa Nuthalapati
    Bo Tong
    Fang Jiang
    Peter Ansell
    Christine K. Ratajczak
    Jasgit Sachdev
    Investigational New Drugs, 2020, 38 : 1815 - 1825
  • [6] A first-in-human, phase 1, dose-escalation study of ABBV-176, an antibody-drug conjugate targeting the prolactin receptor, in patients with advanced solid tumors
    Lemech, Charlotte
    Woodward, Natasha
    Chan, Nancy
    Mortimer, Joanne
    Naumovski, Louie
    Nuthalapati, Silpa
    Tong, Bo
    Jiang, Fang
    Ansell, Peter
    Ratajczak, Christine K.
    Sachdev, Jasgit
    INVESTIGATIONAL NEW DRUGS, 2020, 38 (06) : 1815 - 1825
  • [7] Safety, tolerability, pharmacokinetics, and pharmacodynamics of novel glucokinase activator HMS5552: results from a first-in-human single ascending dose study
    Xu, Hongrong
    Sheng, Lei
    Chen, Weili
    Yuan, Fei
    Yang, Mengjie
    Li, Hui
    Li, Xuening
    Choi, John
    Zhao, Guiyu
    Hu, Tianxin
    Li, Yongguo
    Zhang, Yi
    Chen, Li
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2016, 10 : 1619 - 1626
  • [8] First-in-human phase 1, dose-escalation and -expansion study of ABBV-399, an antibody-drug conjugate (ADC) targeting c-Met, in patients (pts) with advanced solid tumors
    Angevin, E.
    Kelly, K.
    Heist, R.
    Morgensztern, D.
    Weekes, C.
    Bauer, T. M.
    Ramanathan, R. K.
    Nemunaitis, J.
    Fan, X.
    Olyaie, O.
    Parikh, A.
    Reilly, E.
    Afar, D.
    Naumovski, L.
    Strickler, J.
    ANNALS OF ONCOLOGY, 2016, 27
  • [9] Results from a phase 1/2, first-in-human, dose escalation and dose expansion study of an investigational anti-ADAM9 antibody-drug conjugate IMGC936 in patients with advanced solid tumors
    Subbiah, V.
    Falchook, G.
    Davis, A. A.
    Wang, J. S.
    de Miguel, M.
    Santoro, A.
    Maur, M.
    Aljumaily, R.
    Boni, V.
    de Speville, B. Doger
    Sun, Y.
    Du, Y.
    Lakshmikanthan, S.
    Bedse, G.
    Ward, A.
    Zweidler-McKay, P.
    Gandhi, L.
    EUROPEAN JOURNAL OF CANCER, 2024, 211 : S72 - S73
  • [10] A First-in-Human Single- and Multiple-Ascending Dose Study Evaluating Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Novel Oral Nonpeptide GLP-1 Receptor Agonist in Healthy Subjects
    Pratt, Edward J.
    Ma, Xiaosu
    Liu, Rong
    Robins, Deborah A.
    Sloop, Kyle
    Benson, Charles
    DIABETES, 2022, 71
123